Finanzen von MediciNova Inc (MNOV)MNOVMediciNova Inc

Evaluating the bottom line, MediciNova Inc maintains a gross margin of 69.31%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -554.31%, while the net margin is -504.79%. These profitability ratios, combined with a Return on Equity (ROE) of -25.56%, provide a clear picture of how effectively MNOV converts its operational activities into shareholder value.

In the context of the broader market, MNOV competes directly with industry leaders such as TELO and NMRA. With a market capitalization of $71.37M, it holds a significant position in the sector. When comparing efficiency, MNOV's gross margin of 69.31% stands against TELO's N/A and NMRA's N/A. Such benchmarking helps identify whether MediciNova Inc is trading at a premium or discount relative to its financial performance.

MediciNova has shown improving financial performance, particularly with a gross margin of 69.31% in Q2 2026, up from 13.56% in Q2 2025. Total revenue has also increased significantly, reaching $458,439 in Q2 2026 compared to $134,599 in Q2 2025.